Loading...
XLONOVB
Market cap1mUSD
Dec 23, Last price  
1.60GBP
1D
0.00%
1Q
137.04%
Jan 2017
-82.22%
Name

Ovoca Bio PLC

Chart & Performance

D1W1MN
XLON:OVB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-16.22%
-237,000-804,000-5,247,000-855,000-8,609,0002,042,000-3,440,0004,263,000-2,231,000-14,816,000-6,645,000-2,222,000-959,000-381,000-2,356,000-1,590,000-2,348,000-5,496,000-5,612,000-4,702,000
CFO
1m
P
-370,000-463,000-568,000-1,540,000222,0003,409,0002,449,0003,310,0002,260,000-2,817,000-327,000924,000-394,000-1,232,000-2,838,000-2,170,000-2,111,000-4,376,000-5,164,0001,115,000

Profile

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
URL
https://ovocabio.com/
IPO date
Apr 21, 1987
Employees
5
Domiciled in
IE
Incorporated in
IE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
2,285
4,509
5,535
Unusual Expense (Income)
NOPBT
(2,285)
(4,509)
(5,535)
NOPBT Margin
Operating Taxes
336
249
Tax Rate
NOPAT
(2,285)
(4,845)
(5,784)
Net income
(4,702)
-16.22%
(5,612)
2.11%
(5,496)
134.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(3,337)
(3,703)
(6,596)
Cash flow
Cash from operating activities
1,115
(5,164)
(4,376)
CAPEX
(42)
(171)
Cash from investing activities
(49)
1,506
(67)
Cash from financing activities
(879)
900
FCF
(2,285)
(4,827)
(5,601)
Balance
Cash
3,337
3,703
6,594
Long term investments
2
Excess cash
3,337
3,703
6,596
Stockholders' equity
(3,379)
1,323
8,617
Invested Capital
5,880
6,199
6,842
ROIC
ROCE
EV
Common stock shares outstanding
81,564
82
82
Price
0.06
-60.00%
0.15
57.89%
Market cap
5
-60.00%
12
57.89%
EV
(3,698)
(6,584)
EBITDA
(1,985)
(3,978)
(5,451)
EV/EBITDA
0.93
1.21
Interest
39
21
Interest/NOPBT